Literature DB >> 32438207

Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia - data from the OPTiMiSE trial.

Lone Baandrup1, Peter Allerup2, Mette Ø Nielsen3, Nikolaj Bak4, Signe W Düring3, Stefan Leucht5, Silvana Galderisi6, Armida Mucci6, Paola Bucci6, Celso Arango7, Covadonga M Díaz-Caneja7, Paola Dazzan8, Philip McGuire8, Arsime Demjaha8, Bjørn H Ebdrup3, René S Kahn9, Birte Y Glenthøj3.   

Abstract

The observed heterogeneity in negative symptom treatment response may be partly attributable to inadequate measurement tools or limitations in methods of analysis. Previous Item Response Theory models of the Positive and Negative Syndrome Scale (PANSS) have only examined samples of chronic patients and with mixed results. We examined the scalability of the negative subscale embedded in the PANSS and subsequently explored negative symptom trajectories across four weeks of amisulpride treatment. Data were derived from the OPTiMiSE trial comprising 446 patients with first-episode schizophrenia or schizophreniform disorder. Using the Rasch Model to examine psychometric properties of the PANSS negative subscale, we found that the composite score across items was not an adequate measure of negative symptom severity. Consequently, we chose an exploratory statistical approach involving Principal Component Analysis which yielded one significant component clustering into two significant symptom trajectories: 1) Subtle but constant decrease in negative symptom severity (N = 323; 72%), and 2) symptom instability across visits (N = 19; 4%). Explorative analytic methods as presented here may pave the way for more efficient and sensitive methods of analyzing negative symptom response in research and in clinical practice.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Composite score; Item response theory; Rating scale; Symptom relief; Treatment response

Mesh:

Substances:

Year:  2020        PMID: 32438207     DOI: 10.1016/j.psychres.2020.112970

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   11.225


  3 in total

1.  Commentary. Toward a core outcomes assessment set for clinical high risk.

Authors:  Scott W Woods; Catalina V Mourgues-Codern; Albert R Powers
Journal:  Schizophr Res       Date:  2020-05-12       Impact factor: 4.939

2.  Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses.

Authors:  Mette Ødegaard Nielsen; Tina Dam Kristensen; Kirsten Borup Bojesen; Birte Y Glenthøj; Cecilie K Lemvigh; Bjørn H Ebdrup
Journal:  Front Psychiatry       Date:  2022-03-17       Impact factor: 4.157

3.  Scalability of the Positive and Negative Syndrome Scale in first-episode schizophrenia assessed by Rasch models.

Authors:  Lone Baandrup; Peter Allerup; Mette Ø Nielsen; Signe W Düring; Kirsten B Bojesen; Stefan Leucht; Silvana Galderisi; Armida Mucci; Paola Bucci; Celso Arango; Covadonga M Díaz-Caneja; Paola Dazzan; Philip McGuire; Arsime Demjaha; Bjørn H Ebdrup; Wolfgang W Fleischhacker; René S Kahn; Birte Y Glenthøj
Journal:  Acta Psychiatr Scand       Date:  2022-04-22       Impact factor: 7.734

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.